Search Results - "HOHL, R"

Anticoagulants: Major Advances Without Clear Consensus by Hohl, RJ

“…Therapeutics for thrombosis were discovered because of observations made nearly one hundred years ago. The mainstays of these treatments have been either…”
Get full text

Targeted therapies in hematological malignancies by Hohl, R

Get full text

Oncology trial design: More accurately and efficiently advancing the field by Hohl, RJ

Get full text

Drug Development (and Academic Medicine): Charting the Course Forward by Hohl, R J

“…Drug development is both scientifically and economically driven. Past efforts to support the process have had great success, but increasing economic and…”
Get full text

Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma by Gronchi, A., Bui, B.N., Bonvalot, S., Pilotti, S., Ferrari, S., Hohenberger, P., Hohl, R.J., Demetri, G.D., Le Cesne, A., Lardelli, P., Pérez, I., Nieto, A., Tercero, J.C., Alfaro, V., Tamborini, E., Blay, J.Y.

“…To evaluate neoadjuvant trabectedin (1.5 mg/m2 24-h i.v. infusion every 3 weeks; three to six cycles) in patients with locally advanced myoxid liposarcoma (ML)…”
Get full text

Geranylgeranyl Diphosphate Synthase: An Emerging Therapeutic Target by Wiemer, A J, Wiemer, D F, Hohl, R J

“…Proteins modified post‐translationally by geranylgeranylation have been implicated in numerous cellular processes related to human disease. In recent years,…”
Get full text

Schweinfurthin induces ICD without ER stress and caspase activation by Zhang, Ruoheng, Neighbors, J.D., Schell, T.D., Hohl, R.J.

“…Our previous study showed that one of the schweinfurthin compounds, 5'-methoxyschweinfurthin G (MeSG), not only enhances the anti-tumor effect of anti-PD1…”
Get full text

Cancer Therapy: Shooting for the Moon by Lee, JSH, Blumenthal, GM, Hohl, RJ, Huang, S‐M

Get full text

Modeling a seeded continuous crystallizer for the production of active pharmaceutical ingredients by Besenhard, M. O., Hohl, R., Hodzic, A., Eder, R. J. P., Khinast, J. G.

“…The approximation of a well mixed reactor is prevalent when it comes to the modeling of a crystallization process. Since temperature, concentration, and mass…”
Get full text

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse by YUNG, W. K. A, ALBRIGHT, R. E, GLANTZ, M, GREENBERG, H, SELKER, R. G, VICK, N. A, RAMPLING, R, FRIEDMAN, H, PHILLIPS, P, BRUNER, J, YUE, N, OSOBA, D, OLSON, J, ZAKNOEN, S, LEVIN, V. A, FREDERICKS, R, FINK, K, PRADOS, M. D, BRADA, M, SPENCE, A, HOHL, R. J, SHAPIRO, W

“…A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225…”
Get full text

Therapeutic Additions and Possible Deletions in Oncology in 2011 by Holstein, S A, Hohl, R J

“…Approval of agents for the treatment of cancers by the US Food and Drug Administration (FDA) was granted to only six new chemical entities in the three years…”
Get full text

Continuous API-crystal coating via coacervation in a tubular reactor by Besenhard, M.O., Thurnberger, A., Hohl, R., Faulhammer, E., Rattenberger, J., Khinast, J.G.

“…[Display omitted] We present a proof-of-concept study of a continuous coating process of single API crystals in a tubular reactor using coacervation as a…”
Get full text

Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome by Sokol, L, Cripe, L, Kantarjian, H, Sekeres, M A, Parmar, S, Greenberg, P, Goldberg, S L, Bhushan, V, Shammo, J, Hohl, R, Verma, A, Garcia-Manero, G, Li, Y-P, Lowe, A, Zhu, J, List, A F

Get full text

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207 by Rosenberg, J. E., Halabi, S., Sanford, B. L., Himelstein, A. L., Atkins, J. N., Hohl, R. J., Millard, F., Bajorin, D. F., Small, E. J.

“…Background: There is no standard second-line treatment for advanced urothelial carcinoma (UC). Response rates to second-line chemotherapy for advanced UC are…”
Get full text

Imaging as a Biomarker for Therapy Response: Cancer as a Prototype for the Creation of Research Resources by McLennan, G, Clarke, L, Hohl, RJ

Get full text

Clinical Pharmacology as a Foundation for Translational Science by Waldman, SA, Hohl, RJ, Kearns, GL, Swan, SJ, Terzic, A

Get full text

Clinical Pharmacology: Bridging Discovery and Practice by Hohl, R J

Get full text

Exercise training improves cardiorespiratory fitness and cognitive function in individuals with substance use disorders: a pilot study by da Costa, Kell Grandjean, Barbieri, J. F., Hohl, R., Costa, E. C., Fontes, E. B.

“…[...]impaired cognition, such as in decision making and inhibitory control in SUD has been linked to prefrontal cortex dysfunction, which favors impulsive…”
Get full text

Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer by THIBAULT, A, DVORIT SAMID, REED, E, MYERS, C. E, TOMPKINS, A. C, FIGG, W. D, COOPER, M. R, HOHL, R. J, TREPEL, J, LIANG, B, PATRONAS, N, VENZON, D. J

“…Lovastatin, an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (the major regulatory enzyme of the mevalonate pathway of cholesterol…”
Get full text

Vascular Medicine: A Look Forward by Holstein, SA, Hohl, RJ

Get full text